Yahoo España Búsqueda web

Entrar

Search results

  1. www.bignewsnetwork.com › news › 274379518Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha...

    Hace 18 horas · CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix's proprietary RADmAb engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets ...

  2. medicaex.com › prnewswire › telix-completes-proof-of-concept-study-of-tlx592Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha...

    Hace 3 horas · CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets. Initial results demonstrate rapid elimination from blood circulation compared to standard ...